Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 20, pg 233, 2014)

被引：1
|
作者：
Rodon, Jordi [1 ,2 ]
Shapiro, G., I
Bedell, C.
Kwak, E. L.
Baselga, J.
Brana, I
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
来源：
CLINICAL CANCER RESEARCH | 2015年 / 21卷 / 09期
关键词：
D O I：
10.1158/1078-0432.CCR-15-0185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2192 / 2192
页数：1
相关论文
共 50 条
  • [21] Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors
    Abramson, Vandana G.
    Supko, Jeffrey G.
    Ballinger, Tarah
    Cleary, James M.
    Hilton, John F.
    Tolaney, Sara M.
    Chau, Nicole G.
    Cho, Daniel C.
    Pearlberg, Joseph
    Lager, Joanne
    Shapiro, Geoffrey I.
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3520 - 3528
  • [22] Phase I Safety Experience with the Oral Pan-class I PI3K Inhibitor BKM120 in Patients with Metastatic Breast Cancer (mBC)
    Saura, C.
    Burris, H.
    Arteaga, C. L.
    Mayer, I.
    Germa, C.
    Fretault, N.
    Sternberg, D.
    Trandafir, L.
    Massacesi, C.
    Rodon, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S96 - S96
  • [23] First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
    Sarker, Debashis
    Ang, Joo Ern
    Baird, Richard
    Kristeleit, Rebecca
    Shah, Krunal
    Moreno, Victor
    Clarke, Paul A.
    Raynaud, Florence I.
    Levy, Gallia
    Ware, Joseph A.
    Mazina, Kathryn
    Lin, Ray
    Wu, Jenny
    Fredrickson, Jill
    Spoerke, Jill M.
    Lackner, Mark R.
    Yan, Yibing
    Friedman, Lori S.
    Kaye, Stan B.
    Derynck, Mika K.
    Workman, Paul
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2015, 21 (01) : 77 - 86
  • [24] A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors
    Omlin, Aurelius Gabriel
    Spicer, James F.
    Sarker, Debashis
    Pinato, David James
    Agarwal, Roshan
    Cassier, Philippe Alexandre
    Stavraka, Chara
    Blanco, Monsterrat
    Suder, Aneta
    Allan, Suzanne
    Heaton, Simon
    Decordova, Shaun
    Pope, Lorna
    Prince, Jenny
    Noguchi, Kohei
    Jones, Keith
    Inatani, Michiyasu
    Shiokawa, Rie
    Banerji, Udai
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Phase I dose- escalation study of buparlisib ( BKM120), an oral pan- class I PI3K inhibitor, in Japanese patients with advanced solid tumors
    Ando, Yuichi
    Inada-Inoue, Megumi
    Mitsuma, Ayako
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Suenaga, Naoko
    Sato, Masahiko
    Kakizume, Tomoyuki
    Robson, Matthew
    Quadt, Cornelia
    Doi, Toshihiko
    CANCER SCIENCE, 2014, 105 (03) : 347 - 353
  • [26] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [27] Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma
    Brown, Jennifer R.
    Davids, Matthew S.
    Rodon, Jordi
    Abrisqueta, Pau
    DeCillis, Arthur P.
    Rockich, Kevin
    Egile, Coumaran
    Kelly, Adrianne
    Xu, Yi
    Lager, Joanne
    Awan, Farrukh T.
    BLOOD, 2011, 118 (21) : 1153 - 1153
  • [28] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 7, pg 704, 2017)
    Baselga, Jose
    CANCER DISCOVERY, 2018, 8 (11) : 1491 - 1491
  • [29] A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
    Peyton, J. D.
    Ahnert, J. Rodon
    Burris, H.
    Britten, C.
    Chen, L. C.
    Tabernero, J.
    Duval, V.
    Rouyrre, N.
    Silva, A. P.
    Quadt, C.
    Baselga, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] FINAL RESULTS OF PHASE I STUDY OF THE ORAL CLASS I PI3K INHIBITOR CH5132799 IN PATIENTS WITH ADVANCED SOLID TUMOURS
    Suder, A.
    ANNALS OF ONCOLOGY, 2013, 24 : 34 - 35
12345